T1	DISO 148 168	infectados por VIH-1
#1	AnnotatorNotes T1	C2363741; HIV-1 infection; Disease or Syndrome
T2	PROC 173 184	tratamiento
#2	AnnotatorNotes T2	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T3	PROC 214 296	Ensayo clínico fase 2b, aleatorizado, controlado con principio activo, doble ciego
T4	CHEM 387 396	tenofovir
#3	AnnotatorNotes T4	C0384228; tenofovir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T5	CHEM 397 410	emtricitabina
#4	AnnotatorNotes T5	C0909839; emtricitabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T6	DISO 422 442	infectados por VIH-1
#5	AnnotatorNotes T6	C2363741; HIV-1 infection; Disease or Syndrome
T7	PROC 451 462	tratamiento
#6	AnnotatorNotes T7	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T8	PROC 593 620	tratamiento antirretroviral
#7	AnnotatorNotes T8	C1963724; Antiretroviral therapy; Therapeutic or Preventive Procedure
T9	CHEM 703 726	fármaco antirretroviral
#8	AnnotatorNotes T9	C0599685; Anti-Retroviral Agents; Pharmacologic Substance
T10	CHEM 729 742	ARN del VIH-1
#9	AnnotatorNotes T10	C0369499; Human immunodeficiency virus 1 RNA; Nucleic Acid, Nucleoside, or Nucleotide
T11	ANAT 743 753	plasmático
#10	AnnotatorNotes T11	C0032105; Plasma; Body Substance
T12	ANAT 789 805	linfocitos T CD4
#11	AnnotatorNotes T12	C0039215; CD4 Positive T Lymphocytes; Cell
T13	ANAT 813 820	células
#12	AnnotatorNotes T13	C0007634; Cells; Cell | C1269647; Entire cell; Cell
T14	CHEM 899 906	fármaco
#13	AnnotatorNotes T14	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T15	PROC 940 945	tests
#14	AnnotatorNotes T15	C0022885; Laboratory Procedures; Laboratory Procedure (?)
T16	PROC 964 1012	Test de resistencias genotípicas y/o fenotípicas
#15	AnnotatorNotes T16	C0877124; Genotype drug resistance test; Laboratory Procedure | C4696521; Phenotypic lab test method used to determine resistance; Laboratory Procedure
T17	CHEM 1075 1101	inhibidores de la proteasa
#16	AnnotatorNotes T17	C0033607; Protease Inhibitors; Pharmacologic Substance
T18	PROC 1107 1116	protocolo
#17	AnnotatorNotes T18	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T19	PROC 1212 1231	Análisis sanguíneos
#18	AnnotatorNotes T19	C0220847; hepatitis C virus; Virus
T20	ANAT 1221 1231	sanguíneos
#19	AnnotatorNotes T20	C0005767; Blood; Body Substance
T21	CHEM 1060 1063	EFV
#20	AnnotatorNotes T21	C0674428; efavirenz; Organic Chemical · Pharmacologic Substance
T22	DISO 1245 1269	función hepática anormal
#21	AnnotatorNotes T22	C0086565; Liver Dysfunction; Finding
T23	PROC 1275 1284	protocolo
#22	AnnotatorNotes T23	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T24	CHEM 1065 1068	TDF
#23	AnnotatorNotes T24	C0384228; tenofovir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T25	PROC 1314 1323	plaquetas
#24	AnnotatorNotes T25	C0032181; Platelet Count measurement; Laboratory Procedure
T26	ANAT 1333 1340	células
#25	AnnotatorNotes T26	C0007634; Cells; Cell | C1269647; Entire cell; Cell
T27	CHEM 358 368	BMS-955176
#26	AnnotatorNotes T27	C4705990; BMS-955176; Organic Chemical · Pharmacologic Substance
T28	DISO 486 489	VIH
#27	AnnotatorNotes T28	C0458074; Human immunodeficiency virus (HIV) status; Finding
T29	CHEM 605 620	antirretroviral
#28	AnnotatorNotes T29	C0599685; Anti-Retroviral Agents; Pharmacologic Substance
T30	PROC 729 753	ARN del VIH-1 plasmático
T31	PROC 777 805	Recuento de linfocitos T CD4
T32	CHEM 1070 1073	FTC
#29	AnnotatorNotes T32	C0909839; emtricitabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T33	PROC 303 336	investigar la seguridad, eficacia
T34	DISO 1179 1208	Infección crónica por VHB/VHC
T35	DISO 1152 1162	mutaciones
#30	AnnotatorNotes T35	C1705285; Mutation Abnormality; Cell or Molecular Dysfunction
T36	ANAT 1253 1261	hepática
#31	AnnotatorNotes T36	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T37	PROC 1289 1300	Hemoglobina
#32	AnnotatorNotes T37	C0518015; Hemoglobin measurement; Laboratory Procedure
T38	CHEM 91 101	BMS-955176
#33	AnnotatorNotes T38	C4705990; BMS-955176; Organic Chemical · Pharmacologic Substance
T39	PROC 622 625	TAR
#34	AnnotatorNotes T39	C1963724; Antiretroviral therapy; Therapeutic or Preventive Procedure
T40	CHEM 267 283	principio activo
#35	AnnotatorNotes T40	C1372955; Active ingredient; Chemical Viewed Functionally
T41	Date 13 17	2013
T42	Dose 69 87	al menos una dosis
T43	LIVB 140 147	adultos
#36	AnnotatorNotes T43	C0001675; Adult; Age Group
T44	Neg_cue 169 172	sin
T45	LIVB 414 421	adultos
#37	AnnotatorNotes T45	C0001675; Adult; Age Group
T47	LIVB 518 525	Hombres
#38	AnnotatorNotes T47	C0025266; Male population group; Population Group
T48	LIVB 528 535	mujeres
#39	AnnotatorNotes T48	C0043210; Woman; Population Group
T49	Neg_cue 536 538	no
T50	Age 554 581	18 años de edad como mínimo
T51	Neg_cue 645 656	ausencia de
T52	Date 668 674	actual
T53	Duration 686 696	> 1 semana
T54	Observation 853 864	Resistencia
#40	AnnotatorNotes T54	C3542449; Drug Resistance Status; Finding
T55	Observation 867 878	resistencia
#41	AnnotatorNotes T55	C3542449; Drug Resistance Status; Finding
T58	Date 1013 1019	actual
T59	Observation 1046 1057	resistencia
#42	AnnotatorNotes T59	C3542449; Drug Resistance Status; Finding
T61	Duration 1189 1196	crónica
#43	AnnotatorNotes T61	C0205191; chronic; Temporal Concept
T62	LIVB 1205 1208	VHC
#44	AnnotatorNotes T62	C0220847; hepatitis C virus; Virus
T65	PHYS 539 550	embarazadas
#45	AnnotatorNotes T65	C0033011; Pregnant Women; Population Group
T66	LIVB 1201 1204	VHB
#46	AnnotatorNotes T66	C0019169; hepatitis B virus; Virus
T46	Observation 972 984	resistencias
#47	AnnotatorNotes T46	C3542449; Drug Resistance Status; Finding
T56	PHYS 1245 1261	función hepática
#48	AnnotatorNotes T56	C0232741; Liver function; Organ or Tissue Function
T57	LIVB 437 442	VIH-1
#49	AnnotatorNotes T57	C0019704; HIV-1; Virus
T60	LIVB 163 168	VIH-1
#50	AnnotatorNotes T60	C0019704; HIV-1; Virus
T63	LIVB 737 742	VIH-1
#51	AnnotatorNotes T63	C0019704; HIV-1; Virus
A1	Population_data T43 Age
A2	Assertion T2 Negated
A3	Population_data T45 Age
A4	Assertion T65 Negated
A5	Assertion T9 Negated
A6	Status T8 History_of
A7	Assertion T8 Negated
A8	Status T39 History_of
A9	Assertion T39 Negated
A10	Status T9 History_of
A11	Status T59 History_of
A12	Status T21 History_of
A13	Status T24 History_of
A14	Status T32 History_of
A15	Status T17 History_of
#52	AnnotatorNotes T33	C0511730; Identify product efficacy and safety issues; Health Care Activity
#53	AnnotatorNotes T52	C0521116; Current (present time); Temporal Concept 
#54	AnnotatorNotes T58	C0521116; Current (present time); Temporal Concept 
T64	Neg_cue 443 450	naive a
A16	Status T7 History_of
A17	Assertion T7 Negated
T67	Neg_cue 585 592	Naive a
R1	Has_Dose_or_Strength Arg1:T38 Arg2:T42	
R2	Experiences Arg1:T43 Arg2:T38	
T68	Observation 127 135	tolerada
R3	Experiences Arg1:T43 Arg2:T68	
R4	Overlap Arg1:T38 Arg2:T68	
R5	Experiences Arg1:T43 Arg2:T1	
R6	Causes Arg1:T60 Arg2:T1	
R7	Negation Arg1:T44 Arg2:T2	
R8	Experiences Arg1:T43 Arg2:T2	
R9	Combined_with Arg1:T4 Arg2:T5	
R10	Combined_with Arg1:T27 Arg2:T4	
R11	Experiences Arg1:T45 Arg2:T27	
R12	Experiences Arg1:T45 Arg2:T6	
R13	Causes Arg1:T57 Arg2:T6	
R14	Experiences Arg1:T45 Arg2:T7	
R15	Negation Arg1:T64 Arg2:T7	
R16	Has_Age Arg1:T47 Arg2:T50	
R17	Has_Age Arg1:T48 Arg2:T50	
R18	Negation Arg1:T49 Arg2:T65	
R19	Experiences Arg1:T48 Arg2:T65	
R20	Negation Arg1:T67 Arg2:T8	
R21	Negation Arg1:T67 Arg2:T39	
R22	Used_for Arg1:T29 Arg2:T8	
R23	Used_for Arg1:T29 Arg2:T39	
R24	Negation Arg1:T51 Arg2:T9	
R25	Has_Duration_or_Interval Arg1:T9 Arg2:T53	
R26	Overlap Arg1:T9 Arg2:T52	
R27	Used_for Arg1:T9 Arg2:T39	
R28	Used_for Arg1:T9 Arg2:T8	
R29	Location_of Arg1:T11 Arg2:T30	
T69	Result_or_Value 754 774	> o = 1000 copias/ml
R30	Has_Result_or_Value Arg1:T30 Arg2:T69	
T70	Result_or_Value 807 824	> 200 células/mm3
R31	Has_Result_or_Value Arg1:T31 Arg2:T70	
T71	Quantifier_or_Qualifier 879 886	parcial
#55	AnnotatorNotes T71	C0728938; Partial; Quantitative Concept
R32	Has_Quantifier_or_Qualifier Arg1:T55 Arg2:T71	
R33	Overlap Arg1:T54 Arg2:T14	
R34	Overlap Arg1:T55 Arg2:T14	
R35	Overlap Arg1:T54 Arg2:T15	
R36	Overlap Arg1:T54 Arg2:T15	
T72	PROC 952 961	selección
#56	AnnotatorNotes T72	C0242802; Patient Selection; Research Activity (?)
R37	Overlap Arg1:T15 Arg2:T72	
R38	Overlap Arg1:T54 Arg2:T72	
R39	Overlap Arg1:T55 Arg2:T72	
R40	Overlap Arg1:T59 Arg2:T21	
R41	Overlap Arg1:T59 Arg2:T24	
R42	Overlap Arg1:T59 Arg2:T32	
R43	Overlap Arg1:T59 Arg2:T17	
R44	Overlap Arg1:T16 Arg2:T46	
R45	Overlap Arg1:T16 Arg2:T58	
R46	Overlap Arg1:T16 Arg2:T59	
R47	Causes Arg1:T35 Arg2:T59	
R48	Causes Arg1:T35 Arg2:T46	
R49	Causes Arg1:T66 Arg2:T34	
R50	Causes Arg1:T62 Arg2:T34	
R51	Has_Duration_or_Interval Arg1:T34 Arg2:T61	
R52	Location_of Arg1:T20 Arg2:T19	
R53	Location_of Arg1:T36 Arg2:T22	
R54	Location_of Arg1:T36 Arg2:T56	
T73	Result_or_Value 1301 1311	< 8,0 g/dl
R56	Has_Result_or_Value Arg1:T37 Arg2:T73	
T74	Result_or_Value 1324 1344	< 50.000 células/mm3
R57	Has_Result_or_Value Arg1:T25 Arg2:T74	
#57	AnnotatorNotes T68	C5684674; patient tolerated procedure well; Finding
#58	AnnotatorNotes T34	C0524909; Hepatitis B, Chronic; Disease or Syndrome | C0524910; Hepatitis C, Chronic; Disease or Syndrome
#59	AnnotatorNotes T31	C2698595; CD4 Expressing T Cell Count; Laboratory Procedure
A18	Experiencer T43 Patient
A19	Experiencer T45 Patient
A20	Experiencer T47 Patient
A21	Experiencer T48 Patient
